{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:40:31Z","timestamp":1790404831602,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.biopha.2018.10.100","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T12:26:41Z","timestamp":1541420801000},"page":"910-920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats"],"prefix":"10.1016","volume":"109","author":[{"given":"Mamdouh A.","family":"Oraby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed F.","family":"El-Yamany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7238-5403","authenticated-orcid":false,"given":"Marwa M.","family":"Safar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naglaa","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamdy A.","family":"Ghoneim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2018.10.100_bib0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MED.0000000000000074","article-title":"Early diabetic nephropathy in type 1 diabetes\u2013new insights","volume":"21","author":"Bjornstad","year":"2014","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.biopha.2018.10.100_bib0010","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.2337\/diacare.26.10.2903","article-title":"Signs of nephropathy may occur early in young adults with diabetes despite modern diabetes management","volume":"26","author":"Svensson","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2018.10.100_bib0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ki.2009.399","article-title":"In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria","volume":"77","author":"Perkins","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2018.10.100_bib0020","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.2337\/diabetes.52.4.1036","article-title":"Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients","volume":"52","author":"Caramori","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2018.10.100_bib0025","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1172\/JCI45361","article-title":"Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis","volume":"123","author":"Humphreys","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2018.10.100_bib0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/toxsci\/kfs268","article-title":"Novel assays for detection of urinary KIM-1 in mouse models of kidney injury","volume":"131","author":"Sabbisetti","year":"2012","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.biopha.2018.10.100_bib0035","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1623","article-title":"Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies","volume":"28","author":"Vaidya","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2018.10.100_bib0040","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(05)74811-X","article-title":"Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery","volume":"365","author":"Mishra","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2018.10.100_bib0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000208989","article-title":"Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in patients with chronic heart failure and coronary artery disease","volume":"32","author":"Poniatowski","year":"2009","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.biopha.2018.10.100_bib0050","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2337\/dc10-1545","article-title":"Glomerular and tubular damage markers are elevated in patients with diabetes","volume":"34","author":"Nauta","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2018.10.100_bib0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cca.2013.02.019","article-title":"Diabetic nephropathy: Traditional to proteomic markers","volume":"421","author":"Moresco","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.biopha.2018.10.100_bib0060","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1073\/pnas.96.14.7962","article-title":"Nephrin is specifically located at the slit diaphragm of glomerular podocytes","volume":"96","author":"Ruotsalainen","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2018.10.100_bib0065","first-page":"832","article-title":"Developmental expression of the nephritogenic antigen of monoclonal antibody 5-1-6","volume":"147","author":"Kawachi","year":"1995","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2018.10.100_bib0070","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/labinvest.3780332","article-title":"Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy","volume":"81","author":"Aaltonen","year":"2001","journal-title":"Lab. Invest."},{"key":"10.1016\/j.biopha.2018.10.100_bib0075","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0014-5793(00)02110-4","article-title":"Pantetheinase activity of membrane\u2010bound vanin\u20101: lack of free cysteamine in tissues of vanin\u20101 deficient mice","volume":"483","author":"Pitari","year":"2000","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2018.10.100_bib0080","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.etp.2010.10.001","article-title":"Effects of captopril on the cysteamine-induced duodenal ulcer in the rat","volume":"64","author":"Saghaei","year":"2012","journal-title":"Exp. Toxicol. Pathol."},{"key":"10.1016\/j.biopha.2018.10.100_bib0085","doi-asserted-by":"crossref","first-page":"497","DOI":"10.7326\/0003-4819-142-7-200504050-00008","article-title":"Cystatin c concentration as a risk factor for heart failure in older adults","volume":"142","author":"Sarnak","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2018.10.100_bib0090","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.taap.2006.01.003","article-title":"Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress","volume":"212","author":"Rolo","year":"2006","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.biopha.2018.10.100_bib0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1748-717X-5-22","article-title":"Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis","volume":"5","author":"Ong","year":"2010","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.biopha.2018.10.100_bib0100","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2018.10.100_bib0105","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1001\/jama.290.21.2861","article-title":"Isolated pancreas transplantation for type 1 diabetes: A doctor's dilemma","volume":"290","author":"Nathan","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2018.10.100_bib0110","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Epidemiology of diabetes interventions and complications (DCCT\/EDIC) study research group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2018.10.100_bib0115","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2337\/dc06-9912","article-title":"Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the american diabetes association and the european association for the study of diabetes","volume":"29","author":"Nathan","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2018.10.100_bib0120","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.amjmed.2010.11.003","article-title":"Initial combination therapy for type 2 diabetes mellitus: Is it ready for prime time?","volume":"124","author":"Zinman","year":"2011","journal-title":"Am. J. Med."},{"key":"10.1016\/j.biopha.2018.10.100_bib0125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.diabres.2014.02.014","article-title":"SGLT2 inhibitors in the treatment of type 2 diabetes","volume":"104","author":"Hasan","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2018.10.100_bib0130","first-page":"191","article-title":"Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation","volume":"48","author":"Ishibashi","year":"2016","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.biopha.2018.10.100_bib0135","doi-asserted-by":"crossref","first-page":"e00239","DOI":"10.1002\/prp2.239","article-title":"Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose\u2010induced oxidative stress in type 1 diabetic mice","volume":"4","author":"Hatanaka","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.biopha.2018.10.100_bib0140","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.biopha.2018.10.100_bib0145","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2018.10.100_bib0150","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2147\/DMSO.S24159","article-title":"Glycemic control and anti-osteopathic effect of propolis in diabetic rats","volume":"4","author":"Al-Hariri","year":"2011","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.biopha.2018.10.100_bib0155","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1734-1140(12)70739-9","article-title":"Fructose-fed streptozotocin-injected rat: an alternative model for type 2 diabetes","volume":"64","author":"Wilson","year":"2012","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.biopha.2018.10.100_bib0160","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.phrs.2005.05.004","article-title":"Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening","volume":"52","author":"Srinivasan","year":"2005","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2018.10.100_bib0165","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","article-title":"Dapagliflozin, a selective sglt2 inhibitor, improves glucose homeostasis in normal and diabetic rats","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2018.10.100_bib0170","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/210821","article-title":"Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin","volume":"2012","author":"Kim","year":"2012","journal-title":"Exp. Diabetes Res."},{"key":"10.1016\/j.biopha.2018.10.100_bib0175","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/000456326900600108","article-title":"Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor","volume":"6","author":"Trinder","year":"1969","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.biopha.2018.10.100_bib0180","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative pcr and the 2\u2212 \u03b4\u03b4ct method","volume":"25","author":"Livak","year":"2001","journal-title":"methods"},{"key":"10.1016\/j.biopha.2018.10.100_bib0185","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","article-title":"Temporal trends in the prevalence of diabetic kidney disease in the united states","volume":"305","author":"De Boer","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2018.10.100_bib0190","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s13596-015-0193-7","article-title":"Fructose diet and low dose streptozotocin treatment induces the development of diabetic nephropathy in rats","volume":"15","author":"Patel","year":"2015","journal-title":"Orient. Pharm. Exp. Med."},{"key":"10.1016\/j.biopha.2018.10.100_bib0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/DMSO.S22503","article-title":"Targeting the kidney and glucose excretion with dapagliflozin: Preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus","volume":"5","author":"Whaley","year":"2012","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.biopha.2018.10.100_bib0200","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1681\/ASN.2010080888","article-title":"The sweet pee model for Sglt2 mutation","volume":"22","author":"Ly","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2018.10.100_bib0205","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4236\/ojneph.2014.41006","article-title":"Urinary neutrophil gelatinase associated lipocalin as a marker of tubular damage in type 2 diabetic patients with and without albuminuria","volume":"4","author":"Al-Refai","year":"2014","journal-title":"Open J. Nephrol."},{"key":"10.1016\/j.biopha.2018.10.100_bib0210","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/1479164114531299","article-title":"Urinary Kim-1 is a sensitive biomarker for the early stage of diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats","volume":"11","author":"Hosohata","year":"2014","journal-title":"Diab. Vasc. Dis. Res."},{"key":"10.1016\/j.biopha.2018.10.100_bib0215","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ejvs.2016.01.009","article-title":"Neutrophil gelatinase-associated lipocalin (NGAL) is associated with symptomatic carotid atherosclerosis and drives pro-inflammatory state in vitro","volume":"51","author":"Eilenberg","year":"2016","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"10.1016\/j.biopha.2018.10.100_bib0220","doi-asserted-by":"crossref","first-page":"e100777","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2018.10.100_bib0225","doi-asserted-by":"crossref","first-page":"26428","DOI":"10.1038\/srep26428","article-title":"Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db\/db mice","volume":"6","author":"Gallo","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2018.10.100_bib0230","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.nefro.2016.06.011","article-title":"Cystatin-c and TGF-\u03b2 levels in patients with diabetic nephropathy","volume":"36","author":"Takir","year":"2016","journal-title":"Nefrologia"},{"key":"10.1016\/j.biopha.2018.10.100_bib0235","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.etp.2012.06.005","article-title":"Urinary cystatin c as a biomarker for diabetic nephropathy and its immunohistochemical localization in kidney in zucker diabetic fatty (ZDF) rats","volume":"65","author":"Togashi","year":"2013","journal-title":"Exp. Toxicol. Pathol."},{"key":"10.1016\/j.biopha.2018.10.100_bib0240","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/jat.2849","article-title":"Early detection of renal injury using urinary vanin\u20101 in rats with experimental colitis","volume":"34","author":"Hosohata","year":"2014","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.biopha.2018.10.100_bib0245","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2337\/db13-0788","article-title":"Vanin-1 is a key activator for hepatic gluconeogenesis","volume":"63","author":"Chen","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2018.10.100_bib0250","doi-asserted-by":"crossref","first-page":"7214","DOI":"10.1128\/MCB.24.16.7214-7224.2004","article-title":"Vanin-1\u2212\/\u2212 mice exhibit a glutathione-mediated tissue resistance to oxidative stress","volume":"24","author":"Berruyer","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.biopha.2018.10.100_bib0255","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1172\/JCI200419557","article-title":"Vanin-1\u2013\/\u2013mice show decreased NSAID-and schistosoma-induced intestinal inflammation associated with higher glutathione stores","volume":"113","author":"Martin","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2018.10.100_bib0260","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1177\/1479164116657304","article-title":"Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy\/Ta mice, obese and type 2 diabetic animals","volume":"13","author":"Ishibashi","year":"2016","journal-title":"Diab. Vasc. Dis. Res."},{"key":"10.1016\/j.biopha.2018.10.100_bib0265","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12020-011-9509-7","article-title":"Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study","volume":"41","author":"Fu","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.biopha.2018.10.100_bib0270","doi-asserted-by":"crossref","first-page":"4626125","DOI":"10.1155\/2016\/4626125","article-title":"Urinary biomarkers in the assessment of early diabetic nephropathy","volume":"2016","author":"Gluhovschi","year":"2016","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.biopha.2018.10.100_bib0275","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4137\/CMED.S12633","article-title":"Serum cystatin c and tubular urinary enzymes as biomarkers of renal dysfunction in type 2 diabetes mellitus","volume":"6","author":"Assal","year":"2013","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"key":"10.1016\/j.biopha.2018.10.100_bib0280","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/BF02912930","article-title":"Urinary n-acetyl beta glucosaminidase and gamma glutamyl transferase as early markers of diabetic nephropathy","volume":"21","author":"Ambade","year":"2006","journal-title":"Indian J. Clin. Biochem."},{"key":"10.1016\/j.biopha.2018.10.100_bib0285","doi-asserted-by":"crossref","first-page":"218","DOI":"10.5301\/JN.2010.5785","article-title":"Possible involvement of intracellular angiotensin II receptor in high-glucose-induced damage in renal proximal tubular cells","volume":"24","author":"Takao","year":"2010","journal-title":"J. Nephrol."},{"key":"10.1016\/j.biopha.2018.10.100_bib0290","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0034-1395609","article-title":"Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis","volume":"47","author":"Ojima","year":"2015","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.biopha.2018.10.100_bib0295","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1046\/j.1523-1755.2001.00725.x","article-title":"Glomerular cell number in normal subjects and in type 1 diabetic patients","volume":"59","author":"Steffes","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2018.10.100_bib0300","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00041552-199907000-00014","article-title":"The role of the podocyte in glomerulosclerosis","volume":"8","author":"Kriz","year":"1999","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.biopha.2018.10.100_bib0305","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","article-title":"SGLT2 protein expression is increased in human diabetic nephropathy SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice","volume":"292","author":"Wang","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2018.10.100_bib0310","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00535-016-1200-6","article-title":"Ipragliflozin, a sodium\u2013glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic otsuka long\u2013evans tokushima fatty rats","volume":"51","author":"Nishimura","year":"2016","journal-title":"J. Gastroentero."},{"key":"10.1016\/j.biopha.2018.10.100_bib0315","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s001250050012","article-title":"Expression of cytoskeletal proteins during the course of experimental diabetic nephropathy","volume":"43","author":"Sanai","year":"2000","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2018.10.100_bib0320","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/sj.bjp.0706452","article-title":"The immunomodulator FTY720 and its phosphorylated derivative activate the smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells","volume":"147","author":"Xin","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.10.100_bib0325","first-page":"CR235","article-title":"The interstitial expression of alpha-smooth muscle actin in glomerulonephritis is associated with renal function","volume":"18","author":"Novakovic","year":"2012","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.biopha.2018.10.100_bib0330","article-title":"Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury","volume":"11","author":"Chang","year":"2016","journal-title":"PLoS One"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218348406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218348406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:37:27Z","timestamp":1777876647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218348406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":66,"alternative-id":["S0753332218348406"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.10.100","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.10.100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}